Drug Industry Braces For Supreme Court Ruling In Wyeth Pre-emption Case
This article was originally published in The Tan Sheet
This week everyone's attention is riveted on the presidential election. But for the pharmaceutical industry there is another issue just as compelling. On Nov. 3, the U.S. Supreme Court will hear oral arguments in the case that will decide the future of product liability litigation
You may also be interested in...
How the U.S. Supreme Court rules in Wyeth v. Levine could limit the number of product liability suits brought against drug companies
A report from influential House leader Henry Waxman exposes a rift between senior FDA staff and the agency's Office of Chief Counsel that could help the plaintiff in the FDA pre-emption case that has reached the Supreme Court
FDA's final rule on sponsors' obligations to update their labels alters the definition of "newly acquired information" from the proposed rule while leaving the remainder intact. The change could be a boon to industry, but a slap to Democrats who had called for the rule's withdrawal